KRAS mutation responsible for various malignancies, such as NSCLC (25%), colorectal cancer (30∼50%), pancreatic cancer (90%), and is strongly associated with cigarette smoking, therefore, our current preclinical data warrant future studies to evaluate the efficacy of the vaccination against many other KRAS-driven cancer types. This evidence concerns the gene KRAS and pancreatic neoplasm.